talquetamab will improve the degree or result of ergotamine by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor. Talquetamab will cause cytokine release syndrome (CRS) that could suppress activity of CYP enzymes, leading to amplified publicity of CYP substrates.iloperidone will increase amounts of ergotamine by impacting